ArticleJournal of medical primatology2014
A novel real-time CTL assay to measure designer T-cell function against HIV Env(+) cells.
Article in Journal of medical primatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03240328 (The Effect of CAR-T Cell Therapy on the Reconstitution of HIV-specific Immune Function), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of CAR-T Cell Therapy on the Reconstitution of HIV-specific Immune Function
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Simian Immunodeficiency Virus-Derived Extracellular Vesicles Induce a Chronic Inflammatory Phenotype in Healthy Astrocytes Unresolved by Anti-Retroviral Therapy.Pharmaceutics · 2025Article
- Persistence of CMV-specific anti-HIV CAR T cells after adoptive immunotherapy.Journal of virology · 2025Article
- THC reverses SIV-induced senescence in astrocytes: possible compensatory mechanism against HIV associated brain injury?Frontiers in cellular neuroscience · 2025Article
- CAR-T Therapy in HIV: Pioneering Advances and Navigating Challenges.Infectious diseases & immunity · 2024Article
- New Therapies and Strategies to Curb HIV Infections with a Focus on Macrophages and Reservoirs.Viruses · 2024Review
- Article
- Extracellular domain, hinge, and transmembrane determinants affecting surface CD4 expression of a novel anti-HIV chimeric antigen receptor (CAR) construct.bioRxiv : the preprint server for biology · 2023Article
- Strategies for HIV-1 suppression through key genes and cell therapy.Frontiers in medicine · 2023Review
- Advances in HIV-1-specific chimeric antigen receptor cells to target the HIV-1 reservoir.Journal of virus eradication · 2022Article
- Current and Future Therapeutic Strategies for Lentiviral Eradication from Macrophage Reservoirs.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2019Review
- CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV.Frontiers in immunology · 2019Review
- CAR T cells for infection, autoimmunity and allotransplantation.Nature reviews. Immunology · 2018Review
- Chimeric antigen receptor T-cell approaches to HIV cure.Current opinion in HIV and AIDS · 2018Review
- Quarter Century of Anti-HIV CAR T Cells.Current HIV/AIDS reports · 2018Review
- Combining Cell and Gene Therapy in an Effort to Eradicate HIV.AIDS patient care and STDs · 2016Article
- Article
- HIV-1 functional cure: will the dream come true?BMC medicine · 2015Review
- Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity.Journal of virology · 2015Article
- Towards an HIV cure based on targeted killing of infected cells: different approaches against acute versus chronic infection.Current opinion in HIV and AIDS · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundTo increase the immunosurveillance in HIV infection, we used retroviral vectors expressing CD4-chimeric antigen receptors (CARs) to genetically modify autologous T cells and redirect CTL toward HIV. The CD4 extracellular domain targets envelope and the intracellular signaling domains activate T cells. The maC46 fusion inhibitor binds HIV and blocks viral replication.
methodsWe stimulated rhesus PBMCs with antibodies to CD3/CD28 and cotransduced T cells with CD4-CAR and maC46 vectors. CD4-CAR-transduced T cells were added to Env(+) 293T cells at E:T of 1:1. Killing of target cells was measured as reduced impedance.
resultsWe observed gene expression in 60-70% of rhesus CD3(+) CD8(+) T cells with the individual vectors and in 35% of the cells with both vectors. CD4-CAR-transduced populations specifically killed Env(+) cells.
conclusionsIn these studies, we showed that designer T cells were redirected to kill Env(+) cells. Control of viremia without HAART would revolutionize treatment for HIV patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.